| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
KY19334 (5 μM, 72 h) inhibited the proliferation of human squamous cell carcinoma (cSCC) cells HSC-1 and HSC-5, but had no significant inhibitory effect on the proliferation of normal keratinocytes HaCaT[1]. KY19334 (5 μM, 24 h) significantly inhibited the migration and invasion of HSC-1 and HSC-5 cells[1]. KY19334 (5 μM, 2 weeks) inhibited the colony formation of HSC-1 and HSC-5 cells[1]. KY19334 (5 μM, 24 h) downregulated the expression of CDK1 in HSC-1 and HSC-5 cells and inhibited the Wnt/β-catenin signaling pathway[1]. KY19334 (1 mM, 7-16 days) can activate the Wnt/β-catenin signaling pathway in keratinocytes, vascular endothelial cells and fibroblasts in wound tissues of diabetic mice[2]. KY19334 (1 mM, 7 days) can promote the expression of angiogenesis-related proteins in CD31+ vascular endothelial cells in wound tissues of diabetic mice[2].
|
|---|---|
| ln Vivo |
KY19334 (2 mM, topical application, 30 minutes before each TPA) significantly inhibited the development of DMBA and TPA-induced C57BL/6 skin cancer [1]. KY19334 (1 mM, topical application, once daily for 16 consecutive days) promoted wound healing in diabetic C57BL/6 retina [2].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HSC-1 and HSC-5 cells Tested Concentrations: 5 μM Incubation Duration: 24 h Experimental Results: Reduced CDK1 levels by approximately 50%. Did not alter the expression of CDK4. Increased the phosphorylation of β-catenin at Ser33/37/Thr41. Downregulated the expression of downstream target genes c-Myc and Cyclin D1. ELISA Assay[2] Cell Types: CD31+ vascular endothelial cells of diabetic mouse wound tissues Tested Concentrations: 1 mM Incubation Duration: 7 days Experimental Results: Increased VEGFA secretion (approximately 80%), CD31+ capillary density (approximately 75%) and VEGFR2 protein level (approximately 65%). Downregulated the expression of anti-angiogenic factor Serpin F1 (PEDF) (approximately 50%). |
| Animal Protocol |
Animal/Disease Models: DMBA/TPA-induced skin cancer C57BL/6 mice models[1]
Doses: 2 mM Route of Administration: Topically application, 30 mins before each TPA Experimental Results: Decreased tumor numbers and average size. Improved tumor grading. Reduced the proportions of hyperplasia, papilloma and carcinoma in situ. Decreased the proportion of SCC. Downregulated the expressions of CDK1, β-catenin, c-Myc, Cyclin D1 and PCNA in tumor tissues. Upregulated the expressions of tumor suppressor proteins p21Cip/WAF and p27. Animal/Disease Models: HFD (high fat diet)+STZ induced diabetic C57BL/6 mice and db/db mice[2] Doses: 1 mM Route of Administration: Topically application, daily for 16 days Experimental Results: Increased the wound closure rate. Enhanced collagen deposition in wound tissues. Restored the proliferation of Keratin14+ keratinocytes and CD31+ capillary density. Increased nuclear β-catenin expression. |
| References |
| Molecular Formula |
C17H13N3O3
|
|---|---|
| Molecular Weight |
307.30
|
| CAS # |
2319609-67-9
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2541 mL | 16.2707 mL | 32.5415 mL | |
| 5 mM | 0.6508 mL | 3.2541 mL | 6.5083 mL | |
| 10 mM | 0.3254 mL | 1.6271 mL | 3.2541 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
